down arrow

Lantern Pharma, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US51654W1018
USD
2.23
0.00 (0.00%)

Mar 25

NAS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.222.28

52 Week

2.035.74
Valuation
Technical
Day's Volume

CASH

5.09 k

Shareholding (Sep 2025)

FII

0.29%

Held by 8 FIIs

DII

85.59%

Held by 5 DIIs

Promoter

9.42%

How big is Lantern Pharma, Inc.?

22-Jun-2025

As of Jun 18, Lantern Pharma, Inc. has a market capitalization of 33.97 million and reported net sales of 0.00 million with a net profit of -19.89 million over the last four quarters. The balance sheet shows shareholder's funds of 21.19 million and total assets of 25.57 million.

As of Jun 18, Lantern Pharma, Inc. has a market capitalization of 33.97 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a consolidated net profit of -19.89 million during the same period.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 21.19 million and total assets amounting to 25.57 million.

View full answer

What does Lantern Pharma, Inc. do?

22-Jun-2025

Lantern Pharma, Inc. is a clinical stage biotechnology company focused on developing oncology therapies, with a market cap of approximately $33.97 million and a quarterly net loss of $5 million as of March 2025. The company has no dividend yield and negative return on equity.

Overview: <BR>Lantern Pharma, Inc. is a clinical stage biotechnology company focused on developing oncology therapies within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: Not available <BR>Net Profit: -5 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 33.97 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.17 <BR>Return on Equity: -118.48% <BR>Price to Book: 2.02 <BR><BR>Contact Details: <BR>Address: 1920 MCKINNEY AVENUE, 7TH FLOOR, DALLAS TX : 75201 <BR>Tel: 1 972 2771136 <BR>Website: https://www.lanternpharma.com/

View full answer

Who are in the management team of Lantern Pharma, Inc.?

22-Jun-2025

As of March 2022, the management team of Lantern Pharma, Inc. includes Mr. Donald Keyser (Independent Chairman), Mr. Panna Sharma (President and CEO), Dr. David Silberstein, Dr. Vijay Chandru, Mr. Leslie Kreis, and Dr. Franklyn Prendergast (all Independent Directors). They oversee the company's strategic direction and operations.

As of March 2022, the management team of Lantern Pharma, Inc. includes the following individuals:<BR><BR>- Mr. Donald Keyser, who serves as the Independent Chairman of the Board.<BR>- Mr. Panna Sharma, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. David Silberstein, who is a Director.<BR>- Dr. Vijay Chandru, who is an Independent Director.<BR>- Mr. Leslie Kreis, who is also an Independent Director.<BR>- Dr. Franklyn Prendergast, who serves as an Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

View full answer

Is Lantern Pharma, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Lantern Pharma, Inc. shows a mildly bullish trend with mixed technical indicators, including a bullish weekly MACD and bearish monthly RSI, while outperforming the S&P 500 in the past week but underperforming over longer periods.

As of 8 September 2025, the technical trend for Lantern Pharma, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating some positive momentum. However, the monthly RSI is bearish, suggesting weakness in price strength. The daily moving averages are mildly bullish, supporting a short-term positive outlook. The weekly Bollinger Bands are bullish, but the monthly Bollinger Bands are bearish, reflecting mixed signals across time frames. The KST shows a bullish stance weekly and mildly bullish monthly, while the OBV indicates mild bearishness weekly but bullishness monthly.<BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past week with a return of 3.56% compared to 1.05%, but it has underperformed over the past month, year, and longer periods. Overall, the current technical stance is mildly bullish, driven by the mixed indicators across different time frames.

View full answer

Compare Lantern Pharma, Inc. with Similar Stocks

vTv Therapeutics, Inc.Bolt Biotherapeutics, Inc.Daré Bioscience, Inc.
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 27 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.28

stock-summary
Return on Equity

-197.36%

stock-summary
Price to Book

2.81

Revenue and Profits:
Net Sales:
(Quarterly Results - Sep 2025)
Net Profit:
-4 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-33.23%
0%
-33.23%
6 Months
-48.5%
0%
-48.5%
1 Year
-42.08%
0%
-42.08%
2 Years
-77.52%
0%
-77.52%
3 Years
-50.61%
0%
-50.61%
4 Years
-68.77%
0%
-68.77%
5 Years
-88.26%
0%
-88.26%

Lantern Pharma, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-227.76%
EBIT to Interest (avg)
-18.41
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.17
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
24.55%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.81
EV to EBIT
-0.75
EV to EBITDA
-0.75
EV to Capital Employed
-5.48
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-197.36%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 5 Schemes (4.7%)

Foreign Institutions

Held by 8 Foreign Institutions (0.29%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 6.67% vs -40.62% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.30",
          "val2": "-5.10",
          "chgp": "15.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.20",
          "val2": "-4.50",
          "chgp": "6.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -30.00% vs -11.89% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-22.00",
          "val2": "-17.70",
          "chgp": "-24.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-20.80",
          "val2": "-16.00",
          "chgp": "-30.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoYstock-summary

Sep'25
Sep'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-4.30
-5.10
15.69%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-4.20
-4.50
6.67%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 6.67% vs -40.62% in Sep 2024

All Quarterly Resultsstock-summary

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-22.00
-17.70
-24.29%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-20.80
-16.00
-30.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -30.00% vs -11.89% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Lantern Pharma, Inc. stock-summary
stock-summary
Lantern Pharma, Inc.
Pharmaceuticals & Biotechnology
Lantern Pharma Inc. is a clinical stage biotechnology company. The Company is focused on developing oncology therapies. It uses its artificial intelligence (AI) platform, RADR, which includes data points, and uses big data analytics to uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that benefits from its compounds. Its portfolio consists of three compounds: LP-100, LP-300 and LP-184. The Company is developing LP-100 for metastatic, castration-resistant, prostate cancer (mCRPC). LP-300 is a small molecule with cysteine modifying activity on select protein. LP-184, is in a preclinical translational ex vivo study using fresh human biopsies. LP-184 is an alkylating agent with nanomolar potency that preferentially damages deoxyribonucleic acid (DNA) in cancer cells that overexpress certain biomarkers.
Company Coordinates stock-summary
Company Details
1920 MCKINNEY AVENUE, 7TH FLOOR , DALLAS TX : 75201
stock-summary
Tel: 1 972 2771136
stock-summary
https://www.lanternpharma.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Download on App Store
Get it on Google Play
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."